Literature DB >> 25471003

Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.

Sonja A Selemetjev1, Svetlana B Savin, Ivan R Paunovic, Svetislav B Tatic, Dubravka Cvejic.   

Abstract

BACKGROUND: Papillary carcinoma of the thyroid (PTC) is generally a slow growing tumor with favorable prognosis, while anaplastic thyroid carcinoma (ATC) is highly aggressive malignancy. Genetic defects in apoptotic pathways may contribute to differences in their biological behavior.
METHODS: In this study, we analyzed immunohistochemically the expression of apoptosis-related molecules: galectin-3, Bcl-2, survivin (antiapoptotic), and Bax (pro-apoptotic), in archival tissue sections of PTC (n = 69) and ATC (n = 30) and correlated the results with clinicopathological parameters of these tumors.
RESULTS: Galectin-3 and Bcl-2 showed a similar trend of down-regulation from high levels of both in PTC to low levels in ATC (p < 0.05). Bax was expressed at high levels in both type of thyroid carcinoma. Expression of survivin increased from PTC to ATC (p < 0.05), which may, at least in part, further facilitate the ability of malignant thyroid cell of ATC to escape programmed cell death despite high Bax expression. Only survivin, but not galectin-3, Bcl-2, or Bax, correlated significantly with lymph node metastasis presence and advanced stages of malignancy.
CONCLUSIONS: In conclusion, this study documented down-regulation of galectin-3 and Bcl-2 (antiapoptotic molecules) and stepwise increase of survivin (inhibitor of apoptosis), during thyroid tumor progression from PTC to ATC. Correlation of high survivin expression with aggressive behavior implies its role in progression of thyroid tumor malignancy and suggests that survivin could be a useful tool in the prediction of aggressiveness of a subset of papillary carcinomas and a possible target for molecular therapy for ATC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25471003     DOI: 10.1007/s00508-014-0674-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  30 in total

Review 1.  Regulation of apoptosis by Bcl-2 family proteins.

Authors:  Alexandrina Burlacu
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

2.  Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.

Authors:  Dubravka S Cvejic; Svetlana B Savin; Ivana M Petrovic; Ivan R Paunovic; Svetislav B Tatic; Marija J Havelka
Journal:  Head Neck       Date:  2005-12       Impact factor: 3.147

3.  Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.

Authors:  Elena Tirrò; Maria Letizia Consoli; Michele Massimino; Livia Manzella; Francesco Frasca; Laura Sciacca; Luisa Vicari; Giorgio Stassi; Luigi Messina; Angelo Messina; Paolo Vigneri
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

4.  Expression of bcl-2 in papillary thyroid cancers and its prognostic value.

Authors:  M Aksoy; Y Giles; Y Kapran; T Terzioglu; S Tezelman
Journal:  Acta Chir Belg       Date:  2005 Nov-Dec       Impact factor: 1.090

Review 5.  Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Authors:  Alain C Mita; Monica M Mita; Steffan T Nawrocki; Francis J Giles
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

6.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation.

Authors:  K Kawachi; Y Matsushita; S Yonezawa; S Nakano; K Shirao; S Natsugoe; K Sueyoshi; T Aikou; E Sato
Journal:  Hum Pathol       Date:  2000-04       Impact factor: 3.466

Review 7.  Anaplastic thyroid carcinoma: current diagnosis and treatment.

Authors:  D Giuffrida; H Gharib
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

9.  Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma.

Authors:  Alfredo Antonaci; Fabrizio Consorti; Stefania Mardente; Stefania Natalizi; Gloria Giovannone; Carlo Della Rocca
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

10.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

View more
  5 in total

1.  Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level.

Authors:  Joanna Waligórska-Stachura; Nadia Sawicka-Gutaj; Maciej Zabel; Mirosław Andrusiewicz; Paweł Gut; Agata Czarnywojtek; Marek Ruchała
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

2.  Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Weiwei Tang; Congwei Huang; Chongyin Tang; Jin Xu; Hanjin Wang
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

Review 3.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

Review 4.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

5.  Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.

Authors:  Dan Cong; Mengzi He; Silin Chen; Xiaoli Liu; Xiaodong Liu; Hui Sun
Journal:  Onco Targets Ther       Date:  2015-08-26       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.